MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) Files An 8-K Other EventsItem 8.01. Other Events.
On March 21, 2018, Meridian Bioscience, Inc. (the "Company") issued a press release announcing a realignment of its organizational structure. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
(d)Exhibits
| 99.1 |
Press Release of the Company dated March 21, 2018 |
MERIDIAN BIOSCIENCE INC ExhibitEX-99.1 2 pressrelease032118.htm MERIDIAN BIOSCIENCE,…To view the full exhibit click here
About MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO)
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
